HomeBUSINESS
BUSINESS

Kyorin Pres. Says AG Strategy Is a “Success,” Nasonex Eyed as 2nd Battlefield
(Nov.9.2017)

Kyorin Holdings President Minoru Hogawa
Kyorin Holdings’ authorized generic (AG) strategy for Kipres (montelukast), the company’s major product for bronchial asthma and allergic rhinitis, has been a “success,” with AG sales contributing to countering the patent cliff of the original drug, President Minoru Hogawa says ...
(LOG IN FOR FULL STORY)

News Calendar